Your browser doesn't support javascript.
loading
Risk of Chronic Opioid Use After Radiation for Head and Neck Cancer: A Systematic Review and Meta-Analysis.
Zayed, Sondos; Lin, Cindy; Boldt, R Gabriel; Sathya, Jinka; Venkatesan, Varagur; Read, Nancy; Mendez, Lucas C; Moulin, Dwight E; Palma, David A.
Afiliación
  • Zayed S; Department of Radiation Oncology, London Health Sciences Centre, London, Canada.
  • Lin C; Department of Radiation Oncology, London Health Sciences Centre, London, Canada.
  • Boldt RG; Department of Radiation Oncology, London Health Sciences Centre, London, Canada.
  • Sathya J; Department of Radiation Oncology, London Health Sciences Centre, London, Canada.
  • Venkatesan V; Department of Radiation Oncology, London Health Sciences Centre, London, Canada.
  • Read N; Department of Radiation Oncology, London Health Sciences Centre, London, Canada.
  • Mendez LC; Department of Radiation Oncology, London Health Sciences Centre, London, Canada.
  • Moulin DE; Department of Clinical Neurological Sciences and Oncology, London Health Sciences Centre, London, Canada.
  • Palma DA; Department of Radiation Oncology, London Health Sciences Centre, London, Canada.
Adv Radiat Oncol ; 6(2): 100583, 2021.
Article en En | MEDLINE | ID: mdl-33728386
ABSTRACT

PURPOSE:

Opioid addiction is a major public health concern. Chronic opioid use (COU) patterns after radiation for head and neck cancer (HNC) remain poorly understood. The aim of this study was to estimate the prevalence of COU and to identify its risk factors in patients with HNC undergoing curative-intent radiation therapy (RT) or chemoradiotherapy (CRT). METHODS AND MATERIALS We performed a systematic review and meta-analysis using the PubMed (Medline), EMBASE, and Cochrane Library databases, queried from dates of inception until January 2020. COU was defined as persistent use of opioids ≥ 3 months after treatment completion. Meta-analyses were performed using random effects models. Heterogeneity was assessed using the I2 value.

RESULTS:

Seven retrospective studies, reporting on 1841 patients, met the inclusion criteria. Median age was 59.4 (range 56.0-62.0) years with 1343 (72.9%) men and 498 (27.1%) women. Primary tumor locations included oropharynx (n = 891, 48.4%), oral cavity (n = 533, 29.0%), larynx (n = 93, 5.1%), hypopharynx (n = 32, 1.7%), and nasopharynx (n = 29, 1.6%). Eight hundred fifty-four (46.0%) patients had stage I/II and 952 (50.3%) had stage III-IV disease. Three hundred one (16.3%) patients had RT alone, 738 (40.1%) received CRT, and 594 (32.3%) underwent surgery followed by adjuvant RT/CRT. The proportion of patients with HNC who developed COU post-RT/CRT was 40.7% at 3 months (95% confidence interval [CI] 22.6%-61.7%; I2 = 97.1%) and 15.5% at 6 months (95% CI 7.3%-29.7%; I2 = 94.3%). Oropharyngeal malignancies had the highest rate of COU based on primary tumor location (46.6%; 95% CI 30.8%-63.1%; P < .0001). High proportions of COU were found in patients with a history of psychiatric disorder(s) (61.7%), former/current alcohol abuse (53.9%), and opioid requirements before radiation treatment (51.6%; P = .035).

CONCLUSIONS:

A significant proportion of patients who undergo RT for HNC suffer from COU. High-risk factors for COU include an oropharyngeal primary, history of psychiatric disorder, former/current alcohol abuse, and pre-treatment opioid use. New strategies to mitigate COU are needed.

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Idioma: En Revista: Adv Radiat Oncol Año: 2021 Tipo del documento: Article País de afiliación: Canadá

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Idioma: En Revista: Adv Radiat Oncol Año: 2021 Tipo del documento: Article País de afiliación: Canadá